Lenacapavir
Twice-a-year injection that prevents HIV.
- Starts working
- Varies
- Half-life
- 8–12 weeks after injection
- In use since
- 2022
- Pregnancy
- Use with caution
Overview
Lenacapavir is a long-acting HIV medicine given as an injection under the skin every six months. In 2024 trials it prevented virtually all HIV infections, and in 2025 it was approved in the US and EU for PrEP and recommended by WHO.
Conditions it's used for
How it works
Locks HIV's protective shell so it can't unpack or rebuild.
Lenacapavir belongs to the HIV capsid inhibitors. How HIV capsid inhibitors work: lock the protein shell around HIV's genes so the virus can neither unpack in a new cell nor assemble properly.
Uses
- HIV prevention (PrEP)
- Multidrug-resistant HIV treatment (with other drugs)
Available as: subcutaneous injection, tablet (start-up doses).
Typical dose
- Adults
- 927 mg by injection under the skin every 6 months, after a short oral loading phase.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Injection-site lumps, swelling or pain
- Nausea
- Headache
Serious — get medical help
Uncommon, but need prompt attention
- Persistent injection-site nodules
- Resistance if HIV is acquired while levels are low
Warnings
- Test negative for HIV before starting and before each injection
- Don't miss the 6-month appointment window
Interactions
- Rifampicin, carbamazepine — contraindicated
- Strong CYP3A4 inhibitors — levels rise
Other medicines in the atlas that need care with Lenacapavir, grouped by the reason:
Reduced effectModerateWith Carbamazepine, Efavirenz, Enzalutamide, Griseofulvin, Modafinil and 5 more
Enzyme induction lowers levels of this medicine, which may stop it working.
What's usually done: Monitor effect; dose changes or alternatives may be needed. The effect lasts weeks after stopping the inducer.
Raised drug levelsModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more
Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.
What's usually done: A dose reduction, alternative or extra monitoring may be needed.
Pregnancy and breastfeeding
Use with caution
Data are growing; trials included pregnancies without safety signals.
Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.
Brand names
- United States
- Yeztugo (PrEP), Sunlenca (treatment)
- United Kingdom
- Sunlenca
- Europe
- Yeytuo, Sunlenca
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
History
2022
Approved as Sunlenca for multidrug-resistant HIV.
2024
PURPOSE 1 trial: zero HIV infections among over 2,000 women on lenacapavir. Named Science's Breakthrough of the Year.
2025
US approves Yeztugo for PrEP (June); WHO recommends it (July); EU approves (August).
Agreements in 2025 aim to bring generic lenacapavir to many lower-income countries for around US$40 a year.
Common questions
How does it compare with daily PrEP pills?
Both work extremely well when taken properly. Lenacapavir removes the need to remember a daily pill.
Do I need a prescription for Lenacapavir?
Yes — Lenacapavir is prescription-only in most countries.
Can I take Lenacapavir during pregnancy?
Use with caution. Data are growing; trials included pregnancies without safety signals. Always check with a doctor or midwife.
Related medicines
Sources and official information
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.